Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Candidates List: Targets and Possible Therapies for Squamous Cell Carcinoma of the Lung

This article was originally published in RPM Report

Executive Summary

The Friends of Cancer Research has identified 16 potential molecular targets and nearly two dozen drugs in development for use in squamous cell carcinoma of the lung. Organizers of a master protocol registrational trial for SCCL hope to select four therapies to test when the study launches in 2014.

You may also be interested in...

Landmark Trial for Personalized Medicine Coming Soon: NGS Approval May Be One Offshoot of Lung Cancer “Master Protocol”

A Friends of Cancer Research/Brookings proposal for a multi-drug, multi-sponsor registrational study of targeted cancer drugs is moving forward. Squamous cell lung cancer will be the initial indication. If successful, the study could lead to rapid final development of several targeted therapies, a potential route to FDA approval of NextGen Sequencing in oncology—and broad adoption of the “master protocol” model.

A New Start: President Biden Visits Pfizer

President Biden’s relationship with the US pharmaceutical industry is starting out with the starkest contrast imaginable with the initial approach of the Trump Administration – at least on the symbolic level.

US Pharma Faces First Drug Pricing Fight Of 2021

A $16bn provision to increase rebates in the US Medicaid program is a surprise inclusion in the COVID relief package moving through Congress. It looks like an uphill fight for industry to stop it from happening.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts